M Komajda

Summary

Country: France

Publications

  1. ncbi request reprint Case studies: reducing risk in patients with diabetes
    Michel Komajda
    Institut de Cardiologie, Hopital Pitie Salpetriere, Universite Pierre et Marie Curie, Paris, France
    Drugs Today (Barc) 42:37-41. 2006
  2. ncbi request reprint [Idiopathic cardiomyopathies]
    Michel Komajda
    Département de cardiologie Centre hospitalier universitaire La Pitié La Salpêtrière 75651 Paris
    Rev Prat 52:1664-70. 2002
  3. ncbi request reprint Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey
    Michel Komajda
    Department of Cardiology, Pitie Salpetriere Hospital, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Eur Heart J 26:1653-9. 2005
  4. ncbi request reprint Management of heart failure in the elderly: recommendations from the French Society of Cardiology (SFC) and the French Society of Gerontology and Geriatrics (SFGG)
    M Komajda
    Department of Cardiology, Pitie Salpetriere Hospital, 47 83 boulevard de l Hopital, 75013 Paris, France
    J Nutr Health Aging 10:434-44. 2006
  5. pmc Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study)
    Michel Komajda
    Université Pierre et Marie Curie Paris 6 Assistance Publique Hôpitaux de Paris, Hopital Pitie Salpetriere, Paris, France
    Cardiovasc Diabetol 7:10. 2008
  6. ncbi request reprint Ambulatory heart failure management in private practice in France
    M Komajda
    Service de cardiologie, Hopital Pitie Salpetriere, 47 83 Bd de l Hopital, 75013 Paris, France
    Eur J Heart Fail 3:503-7. 2001
  7. ncbi request reprint The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET
    Michel Komajda
    Institut de Cardiologie, Hopital Pitie Salpetriere, Universite Pierre et Marie Curie, 47 83 bld de l Hôpital, Paris, France
    Eur Heart J 27:1440-6. 2006
  8. ncbi request reprint [Observations on the management of cardiac failure in ambulatory patients. Results of a survey of cardiologists]
    M Komajda
    Service de cardiologie, , 47-83, , 75013 Paris
    Arch Mal Coeur Vaiss 94:257-61. 2001
  9. ncbi request reprint Charcot-Marie-Tooth features and maculopathy in a patient with Danon disease
    P Laforet
    Institut de Myologie, Batiment Babinski, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75113 Paris Cedex, France
    Neurology 63:1535. 2004
  10. ncbi request reprint [Noninvasive evaluation of partial beta adrenergic agonist properties of xamoterol in cardiac insufficiency]
    M Richaud
    Service de cardiologie, CHU Pitie Salpetriere, Paris
    Arch Mal Coeur Vaiss 83:247-52. 1990

Collaborators

Detail Information

Publications101 found, 100 shown here

  1. ncbi request reprint Case studies: reducing risk in patients with diabetes
    Michel Komajda
    Institut de Cardiologie, Hopital Pitie Salpetriere, Universite Pierre et Marie Curie, Paris, France
    Drugs Today (Barc) 42:37-41. 2006
  2. ncbi request reprint [Idiopathic cardiomyopathies]
    Michel Komajda
    Département de cardiologie Centre hospitalier universitaire La Pitié La Salpêtrière 75651 Paris
    Rev Prat 52:1664-70. 2002
    ..This completely new knowledge should lead to the development of new therapeutic strategies...
  3. ncbi request reprint Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey
    Michel Komajda
    Department of Cardiology, Pitie Salpetriere Hospital, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Eur Heart J 26:1653-9. 2005
    ..We investigated the consequences of adherence to care by cardiologists on the rate of CHF and cardiovascular (CV) hospitalizations and time to CV hospitalization...
  4. ncbi request reprint Management of heart failure in the elderly: recommendations from the French Society of Cardiology (SFC) and the French Society of Gerontology and Geriatrics (SFGG)
    M Komajda
    Department of Cardiology, Pitie Salpetriere Hospital, 47 83 boulevard de l Hopital, 75013 Paris, France
    J Nutr Health Aging 10:434-44. 2006
    ..The therapeutic programmes in which multidisciplinary teams are involved reduce the number and duration of hospitalisations and the costs generated by the disease...
  5. pmc Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study)
    Michel Komajda
    Université Pierre et Marie Curie Paris 6 Assistance Publique Hôpitaux de Paris, Hopital Pitie Salpetriere, Paris, France
    Cardiovasc Diabetol 7:10. 2008
    ..We therefore used ambulatory BP to quantify BP lowering at 6-12 months with rosiglitazone used in combination with metformin or sulfonylureas compared to metformin and sulfonylureas in people with type 2 diabetes...
  6. ncbi request reprint Ambulatory heart failure management in private practice in France
    M Komajda
    Service de cardiologie, Hopital Pitie Salpetriere, 47 83 Bd de l Hopital, 75013 Paris, France
    Eur J Heart Fail 3:503-7. 2001
    ..Beta-blockers were given to only 14% of the patients. In patients aged over 80 years, only 45% received angiotensin converting enzyme inhibitors...
  7. ncbi request reprint The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET
    Michel Komajda
    Institut de Cardiologie, Hopital Pitie Salpetriere, Universite Pierre et Marie Curie, 47 83 bld de l Hôpital, Paris, France
    Eur Heart J 27:1440-6. 2006
    ..Anaemia is a common comorbidity in chronic heart failure (CHF). The predictors of new onset anaemia (NOA) and its long-term prognostic value, particularly in patients treated with beta-blockers, are not known...
  8. ncbi request reprint [Observations on the management of cardiac failure in ambulatory patients. Results of a survey of cardiologists]
    M Komajda
    Service de cardiologie, , 47-83, , 75013 Paris
    Arch Mal Coeur Vaiss 94:257-61. 2001
    ..The prescription of betablockers remains marginal. The reason for the underprescription of recommended drugs (International Recommendations) would justify further investigation...
  9. ncbi request reprint Charcot-Marie-Tooth features and maculopathy in a patient with Danon disease
    P Laforet
    Institut de Myologie, Batiment Babinski, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75113 Paris Cedex, France
    Neurology 63:1535. 2004
  10. ncbi request reprint [Noninvasive evaluation of partial beta adrenergic agonist properties of xamoterol in cardiac insufficiency]
    M Richaud
    Service de cardiologie, CHU Pitie Salpetriere, Paris
    Arch Mal Coeur Vaiss 83:247-52. 1990
    ..001), the systolic blood pressure (p less than 0.01), the rate-pressure product (p less than 0.001) and the cardiac index (p less than 0.001) produced by the administration of dobutamine...
  11. pmc Genetic testing and genetic counselling in hypertrophic cardiomyopathy: the French experience
    P Charron
    Service de cardiologie, Hopital Pitie Salpetriere, Paris, France
    J Med Genet 39:741-6. 2002
    ..We decided to perform no prognostic testing...
  12. ncbi request reprint Variations in plasma endothelin concentrations during coronary spasm
    J Y Artigou
    Cardiology Department, Hopital Pitie Salpetriere, Paris, France
    Eur Heart J 14:780-4. 1993
    ..The endothelin level increased significantly during spasm in Group I patients. The plasma concentration of endothelin appeared to be higher in the basal state and during spasm in patients exhibiting spastic angina...
  13. ncbi request reprint Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure
    R Isnard
    Service de cardiologie, Institut Fédératif de Recherche 14 Heart, vessels, muscle Hôpital Pitié Salpêtrière, Paris, France
    Am J Cardiol 86:417-21. 2000
    ..Measurement of plasma neurohormones should therefore be considered routinely as a complementary or alternative tool for identifying high-risk patients with moderate CHF...
  14. ncbi request reprint Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN)
    Michel Komajda
    Institut de Cardiologie, Centre Hospitalier GH Pitié Salpêtrière, 47 83 bld de l Hôpital, 75013, Paris Cedex 13, France
    Eur J Heart Fail 6:467-75. 2004
    ..Management guidelines for heart failure recommend ACE-I and beta-blockers. The perception of difficult up-titration might have added to the slow uptake of beta-blockers despite their mortality and morbidity benefits...
  15. ncbi request reprint Accuracy of European diagnostic criteria for familial hypertrophic cardiomyopathy in a genotyped population
    P Charron
    Service de cardiologie, Hopital Pitie Salpetriere, Paris, France
    Int J Cardiol 90:33-8; discussion 38-40. 2003
    ..However, their diagnostic value remains unknown. The aim of the study was to evaluate the accuracy of these new criteria, using the genetic status as the criterion of reference...
  16. pmc Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations
    P Sebillon
    Laboratoire Génétique et Insuffisance Cardiaque, Association Claude Bernard Université Paris VI, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Med Genet 40:560-7. 2003
    ..The aim of this study was to perform a mutational analysis of LMNA in a large white population of patients affected by dilated cardiomyopathy with or without associated symptoms...
  17. ncbi request reprint [Physiopathology of mitral mechanics in hypertrophic cardiomyopathy. Groupe de travail "Cardiomyopathies et insuffisance cardiaque" de la Société Française de Cardiologie]
    A Hagege
    Service de cardiologie, Hopital Boucicaut, Paris
    Arch Mal Coeur Vaiss 87:1345-52. 1994
    ..The recognition of these abnormalities is of value from the therapeutic (mitral valvuloplasty) diagnostic (in borderline cases) and genetic (when the primary nature of the abnormalities is confirmed) points of view...
  18. ncbi request reprint Improving outcomes in chronic heart failure
    Michel Komajda
    Institut de Cardiologie, Hopital Pitie Salpetriere, Universite Pierre et Marie Curie, Paris, France
    Drugs Today (Barc) 42:29-36. 2006
    ..Candesartan also significantly reduced the risk of new-onset diabetes and of atrial fibrillation in the CHARM-Overall study...
  19. ncbi request reprint [Review: genetics of familial dilated cardiomyopathy]
    M E Amara
    Service de cardiologie, CHI Le Raincy Montfermeil, 10, rue du General Leclerc, 93370 Montfermeil, France
    Ann Cardiol Angeiol (Paris) 54:151-6. 2005
    ..This review indicates the genes and proteins implicated in the pathogeny of familial dilated cardiomyopathy, and their potential clinical effects...
  20. pmc Relation between QT duration and maximal wall thickness in familial hypertrophic cardiomyopathy
    X Jouven
    Service de cardiologie, Hopital Europeen Georges Pompidou, Paris, France
    Heart 88:153-7. 2002
    ..QT abnormalities have been reported in left ventricular hypertrophy and hypertrophic cardiomyopathy...
  21. ncbi request reprint [Analysis of predictive factors of mortality in dilated cardiomyopathy. A cooperative study by the Cardiomyopathy Working Group]
    M Komajda
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 83:899-906. 1990
    ....
  22. pmc Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey
    P Charron
    Département de génétique, Batiment Babinski, Hopital Pitie Salpetriere, 47 Blvd de l Hopital, 75856 Cedex 13, Paris, France
    Heart 90:842-6. 2004
    ..However, extensive genetic screening failed to identify a mutation in about a third of cases. One possible explanation is that other diseases, caused by other genes, may mimic HCM...
  23. ncbi request reprint Are we ready for pharmacogenomics in heart failure?
    P Charron
    Service de cardiologie, et Association Claude Bernard Université Paris VI, Hopital Pitie Salpetriere, 47 83, Boulevard de l Hopital, 75013, Paris, France
    Eur J Pharmacol 417:1-9. 2001
    ....
  24. ncbi request reprint [Genetics of hypertrophic cardiomyopathies: what are the clinical perspectives?]
    M Komajda
    Service de cardiologie, CHU Pitie Salpetriere, Paris
    Arch Mal Coeur Vaiss 89:11-4. 1996
    ..The genetic heterogeneity of the disease is a limiting factor in genetic counselling and there are ethical problems related to the absence of effective treatment...
  25. ncbi request reprint A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination
    Jean Sebastien Hulot
    Department of Pharmacology, Pitie Salpetriere University Hospital, Assistance Publique Hopitaux de Paris, Pierre et Marie Curie University, Paris, France
    Pharmacogenet Genomics 15:277-85. 2005
    ..Candidates for methotrexate therapy should be considered for MRP2 functional testing...
  26. ncbi request reprint Severe dilated cardiomyopathy and quadriceps myopathy due to lamin A/C gene mutation: a phenotypic study
    Jean Christophe Charniot
    Service de cardiologie, Avicenne Hospital, Paris XIII University, Bobigny, France
    Eur J Heart Fail 8:249-56. 2006
    ..This study reports a family affected by a new phenotype associated with dilated cardiomyopathy and quadriceps myopathy...
  27. ncbi request reprint Consensus of the French Society of Gerontology and Geriatrics and the French Society of Cardiology for the management of coronary artery disease in older adults
    Olivier Hanon
    Department of Geriatrics, Universite Paris Descartes, Hopital Broca, 54 56, rue Pascal, 75013 Paris, France
    Arch Cardiovasc Dis 102:829-45. 2009
    ....
  28. ncbi request reprint Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy
    Pascale Richard
    UF de Cardiogénétique et Myogénétique, Service de Biochimie B, Hopital de la Salpetriere, 47 Bld de l Hopital, 75651 Paris Cedex 13, France
    Circulation 107:2227-32. 2003
    ..The aim of the present study was to perform a systematic screening of these genes in a large population, to evaluate the distribution of the disease genes, and to determine the best molecular strategy in clinical practice...
  29. ncbi request reprint Molecular genetics in hypertrophic cardiomyopathy: towards individualized management of the disease
    Philippe Charron
    Centre of Reference for Cardiac Hereditary Diseases, Département de génétique, Hopital Pitie Salpetriere, 47 Boulevard de l Hopital, 75013 Paris, France
    Expert Rev Mol Diagn 6:65-78. 2006
    ..This review focuses on the impact of the molecular data on the understanding of the disease, and considers the emerging issues regarding the impact of molecular testing on the management of patients (or relatives) in clinical practice...
  30. ncbi request reprint Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure
    Richard Isnard
    Service de cardiologie, Institut Fédératif de Recherche 14 Heart, vessels, muscle UPRES EA 2390, Hopital Pitie Salpetriere, AP HP, Paris, France
    Am Heart J 146:729-35. 2003
    ..The purpose of this study was to assess whether plasma B-type natriuretic peptide (BNP) provided any additional prognostic information...
  31. ncbi request reprint [Atrial natriuretic factor and cardiac insufficiency]
    M Komajda
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 85:473-7. 1992
    ..Inhibitors of the enzyme degrading the peptide, neutral endopeptidase, are under evaluation in clinical trials which are at a preliminary stage for the moment...
  32. ncbi request reprint [Role of arterial hypertension in the cardiac involvement of acromegaly]
    D Morvan
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 83:1507-13. 1990
    ..Hypertension plays a significant role in the development of this hypertrophy. Left ventricular systolic function is normal but diastolic function is impaired...
  33. ncbi request reprint [Nitrate derivatives and cardiac insufficiency]
    M Komajda
    , Service de cardiologie, Paris
    Arch Mal Coeur Vaiss 85:29-32. 1992
    ..Tolerance seems to be related to neuro-hormonal factors and perhaps to depletion of SH groups. Simultaneous use of nitrates and ACE inhibitors seems to be an interesting therapeutic concept...
  34. ncbi request reprint [Treatment of chronic heart failure: current views]
    M Komajda
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 88:603-6. 1995
    ..However, new molecules such as vesnarininone or pimobendan are under trial. Finally, in the next few years, the introduction of antagonists to Angiotensin II receptors is eagerly awaited...
  35. doi request reprint Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II
    Michel Komajda
    AP HP, Department of Cardiology, Pitie Salpetriere Hospital, University Pierre et Marie Curie Paris 6, Paris, France
    Eur Heart J 30:478-86. 2009
    ..International guidelines are frequently not implemented in the elderly population with heart failure (HF). This study determined the management of octogenarians with HF enrolled in Euro Heart Failure Survey II (EHFS II) (2004-05)...
  36. ncbi request reprint Prevalence of anemia in patients with chronic heart failure and their clinical characteristics
    Michel Komajda
    Institut de Cardiologie, GH Pitié Salpétrière, Paris, France
    J Card Fail 10:S1-4. 2004
    ....
  37. ncbi request reprint Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I
    Michel Komajda
    Department of Cardiology, Pitie Salpetriere Hospital, University Pierre et Marie Curie, 47 83 boulevard de l Hopital, 75013 Paris, France
    Eur Heart J 28:1310-8. 2007
    ..Here, the aim is to study the management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I. Heart Failure (HF) is common in older people and associated with poor outcome...
  38. ncbi request reprint Mutation screening in dilated cardiomyopathy: prominent role of the beta myosin heavy chain gene
    Eric Villard
    INSERM Unité 621, IFR14, CIB Pitié Salpêtrière, 91 Bd de l Hopital, 75013 Paris, France
    Eur Heart J 26:794-803. 2005
    ..Here, we performed a mutation analysis of four genes involved in FDCM in a population of idiopathic DCM...
  39. ncbi request reprint [Myocardial involvement in 2 women, carriers of Duchenne de Boulogne muscular dystrophy]
    J P Rinaldi
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 84:401-4. 1991
    ..They presented with apparently idiopathic dilated cardiomyopathies. These cases show that Duchenne muscular dystrophy is an original example of a genetically determined diffuse muscular disease with cardiac involvement...
  40. ncbi request reprint [Atrial natriuretic factor, catecholamines and the renin-angiotensin system in cardiac insufficiency. Relation to hemodynamic parameters]
    M Komajda
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 81:845-53. 1988
    ..57, p less than 0.02), mean pulmonary capillary pressure (r = 0.62, p less than 0.001), cardiac index (r = 0.53, p less than 0.05) and left ventricular end-diastolic pressure (r = 0.58, p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)..
  41. ncbi request reprint [HLA A-B and DR in dilated myocardiopathies]
    M Komajda
    Service de cardiologie, , Paris, France
    Arch Mal Coeur Vaiss 80:1233-7. 1987
    ....
  42. ncbi request reprint [Mortality in cardiac insufficiency. Evaluation of prognosis, influence of treatments]
    M Komajda
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 83:1975-80. 1990
    ..Only randomised, multicentre therapeutic trials in comparable groups of patients can provide information about the effects of medical treatment on the long-term prognosis of cardiac failure...
  43. ncbi request reprint [Silent Q fever endocarditis. Report of a case]
    P Jourdain
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 92:915-7. 1999
    ..Transthoracic and transoesophageal echocardiography should be widely used in acute forms of Q fever and systematic in chronic infections with Coxiella Burnetti...
  44. ncbi request reprint [Cardiac insufficiency: what treatment? what dose? For which patients? Converting enzyme inhibitors and diuretics]
    M Komajda
    Service de cardiologie, CHU la Pitié Salpétrière, Paris
    Arch Mal Coeur Vaiss 93:13-6. 2000
    ..The results of this study incite the prescription of high rather than low doses of angiotensin converting enzyme inhibitor...
  45. ncbi request reprint Genotype-phenotype analysis in four families with mutations in beta-myosin heavy chain gene responsible for familial hypertrophic cardiomyopathy
    F Tesson
    INSERM UR 153, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Hum Mutat 12:385-92. 1998
    ..Additional family studies are needed to confirm these findings and to contribute to stratify the prognosis according to the mutation involved...
  46. ncbi request reprint Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial
    Lars G Olsson
    Department of Emergency and Cardiovascular Medicine Sahlgrenska Academy, Goteborg University, Goteborg, Sweden, and Department of Cardiology, La Pitie Salpetriere Hospital, Paris, France
    Eur J Heart Fail 9:795-801. 2007
    ..Beta-blockers (BB) may influence these levels but it is unclear whether changes in NT-pro BNP reflect concomitant changes in prognosis...
  47. pmc Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
    Michel Komajda
    Universite Pierre et Marie Curie Paris 6, Paris, France
    Eur Heart J 31:824-31. 2010
    ..We assessed fatal and non-fatal HF events and their outcome, and identified HF predictors in the RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes) trial population...
  48. ncbi request reprint Mutational analysis of the beta- and delta-sarcoglycan genes in a large number of patients with familial and sporadic dilated cardiomyopathy
    Nicolas Sylvius
    Laboratoire de génétique et insuffisance cardiaque, Association Claude Bernard Université Paris VI, Groupe Hospitalier Pitie Salpetriere, 47 Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Am J Med Genet A 120:8-12. 2003
    ....
  49. ncbi request reprint Functional consequences of an LMNA mutation associated with a new cardiac and non-cardiac phenotype
    Jean Christophe Charniot
    Service de cardiologie, Avicenne Hospital, Bobigny, France
    Hum Mutat 21:473-81. 2003
    ..This new phenotype points out the wide spectrum of neuromuscular and cardiac manifestations associated with lamin A/C mutations, with the functional consequence of this mutation seemingly associated with a disorganization of the lamina...
  50. ncbi request reprint Relationships between the antihypertensive effects of bisoprolol and levels of plasma atrial natriuretic peptide in hypertensive patients
    Beáta Baláti
    Services de Pharmacologie, Hopital Pitie Salpetriere, Paris, France
    Fundam Clin Pharmacol 16:361-8. 2002
    ..49, P = 0.035). These results suggest that the antihypertensive effect of beta-blocking agents could be partly mediated by an increase of ANP release...
  51. ncbi request reprint Apical left ventricular aneurysm without atrio-ventricular block due to a lamin A/C gene mutation
    Jean François Forissier
    Service de cardiologie, Hopital Ambroise Pare, Boulogne Billancourt, France
    Eur J Heart Fail 5:821-5. 2003
    ..Three of these disorders affect cardiac and/or skeletal muscles with atrio-ventricular conduction disturbances, dilated cardiomyopathy and sudden cardiac death as common features...
  52. ncbi request reprint Thromboembolism in heart failure, old ideas and new challenges
    R Isnard
    Cardiology Department, Hopital Pitie Salpetriere, 47 Boulevard de l Hopital, 75651 Cedex 13, Paris, France
    Eur J Heart Fail 3:265-9. 2001
    ..The objective of this paper is to review the available evidence in the absence of the results of large ongoing trials...
  53. ncbi request reprint Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study
    L Tiret
    INSERM U525, Paris, France
    J Am Coll Cardiol 35:29-35. 2000
    ..The study investigated the potential role of eight candidate genes in the susceptibility to idiopathic dilated cardiomyopathy (IDC)...
  54. pmc A new locus for autosomal dominant dilated cardiomyopathy identified on chromosome 6q12-q16
    N Sylvius
    Laboratoire Génétique et Insuffisance Cardiaque, Association Claude Bernard Université Paris VI, and IFR 14 Coeur, Muscles et Vaisseaux, Paris, France
    Am J Hum Genet 68:241-6. 2001
    ..The phospholamban, malic enzyme 1-soluble, and laminin-alpha4 genes were excluded as candidate genes, using single-strand conformation polymorphism or linkage analysis...
  55. ncbi request reprint [The ATLAS study (Assessment of Treatment with Lisinopril and Survival); justification and objectives]
    M Komajda
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 87:45-50. 1994
    ..In cases of intolerance, the dosage may be reduced to 20 mg/day or 10 mg/day, or the drug may be withdrawn.(ABSTRACT TRUNCATED AT 250 WORDS)..
  56. ncbi request reprint Are angiotensin II receptor antagonists indicated in chronic heart failure?
    Michel Komajda
    Department of Cardiology, Pitie Salpetriere Hospital, Paris, France
    Heart Fail Monit 2:85-7. 2002
    ..However, much more information should be available in the next few years, which will provide more evidence on how to use ARAs and in which patients...
  57. ncbi request reprint Genes and their polymorphisms in mono- and multifactorial cardiomyopathies: towards pharmacogenomics in heart failure
    Philippe Charron
    Department of Cardiology and Genetics Laboratory, Association Claude Bernard, Universite Paris VI, Hopital Pitie Salpetriere, Paris, France
    Pharmacogenomics 3:367-78. 2002
    ..Preliminary data suggest interactions between pharmacological treatment and genetic polymorphisms, which appear to be the first steps towards the application of pharmacogenetics in heart failure...
  58. doi request reprint Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes
    Alexandre Mebazaa
    Hôpital Lariboisière APHP, University Paris 7 Diderot, Paris, France
    Crit Care Med 36:S129-39. 2008
    ..Rather, they are meant to serve as a tool to facilitate guideline implementation where data are available and to provide suggested treatment approaches where formal guidelines and definitive evidence are lacking...
  59. ncbi request reprint Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy
    J Flavigny
    Biochimie B, and IFR de Physiopathologie et de Génétique Cardiovasculaire, Hopital Pitie Salpetriere, Paris, France
    J Mol Med (Berl) 76:208-14. 1998
    ....
  60. pmc Double heterozygosity for mutations in the beta-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy
    P Richard
    Service de Biochimie B, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Med Genet 36:542-5. 1999
    ..This double heterozygosity is not lethal but is associated with a more severe phenotype...
  61. ncbi request reprint Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy
    J F Forissier
    Unité de Recherches 153 de l INSERM, Paris, France
    Circulation 94:3069-73. 1996
    ....
  62. ncbi request reprint Prenatal molecular diagnosis in hypertrophic cardiomyopathy: report of the first case
    Philippe Charron
    Département de génétique, cytogénétique et embryologie, Hopital Pitie Salpetriere, Paris, France
    Prenat Diagn 24:701-3. 2004
    ..To the best of our knowledge, this is the first report of a prenatal molecular diagnosis performed in the context of HCM...
  63. ncbi request reprint Lessons from the European heart survey
    Michel Komajda
    Hopital Pitie Salpetriere, Paris, France
    Circulation 113:f25-6. 2006
  64. doi request reprint Feasibility of outpatient coronary angiography with "ad hoc" angioplasty
    Arnaud Chaumeil
    Institute of Cardiology, Pitié Salpêtrière Hospital Group, 47 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Arch Cardiovasc Dis 101:383-90. 2008
    ..It combines the advantages of increased convenience for the patient and lower costs...
  65. ncbi request reprint A familial form of conduction defect related to a mutation in the PRKAG2 gene
    Philippe Charron
    Universite Pierre et Marie Curie Paris 6, Inserm UMR621, AP HP, Hopital Pitie Salpetriere, Departement de Cardiologie, Paris, France
    Europace 9:597-600. 2007
    ..These findings extend the phenotype associated with the PRKAG2 gene and emphasize an additional cause of familial conduction defect...
  66. doi request reprint Long-term outcome after bare-metal or drug-eluting stenting for allograft coronary artery disease
    Farzin Beygui
    Cardiology Department, Pitie Salpetriere University Hospital, Paris, France
    J Heart Lung Transplant 29:316-22. 2010
    ..We aimed to assess the outcome of successful PCI with BMS or drug-eluting stenting (DES) in such patients...
  67. ncbi request reprint Highlights of the 2006 scientific sessions of the European Society of Cardiology: Barcelona, Spain, September 2-5, 2006
    Jeroen J Bax
    Leiden University Medical Center, Leiden, The Netherlands
    J Am Coll Cardiol 48:2564-74. 2006
  68. ncbi request reprint [Management of heart failure in the elderly patient]
    Michel Komajda
    Service de Cardiologie médicale, Institut de Cardiologie, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris 13
    Bull Acad Natl Med 190:817-24; discussion 824-5, 873-6. 2006
    ..The results show that diagnostic investigations and treatment modalities do not comply with international guidelines. The in-hospital and 12-week mortality rates were high...
  69. ncbi request reprint Review of current and investigational pharmacologic agents for acute heart failure syndromes
    David D Shin
    Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA, and Division of Cardiology, European Hospital, Rome, Italy
    Am J Cardiol 99:4A-23A. 2007
    ..This article reviews a selection of current and investigational agents for the treatment of AHFS, with a main focus on the high-risk patient population with AHFS/LO...
  70. doi request reprint Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II
    Markku S Nieminen
    Division of Cardiology, Department of Medicine, Helsinki University Central Hospital, Finland
    Eur J Heart Fail 10:140-8. 2008
    ..This analysis evaluates the gender differences in patients hospitalised for acute heart failure (AHF) in the EuroHeart Failure Survey II (EHFS)...
  71. ncbi request reprint Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology
    Marco Metra
    Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy
    Eur J Heart Fail 9:684-94. 2007
    ..These patients deserve effective therapeutic options and should be potential targets for future clinical research initiatives...
  72. ncbi request reprint Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis
    Philip D Home
    Newcastle Diabetes Centre and Newcastle University, Newcastle upon Tyne, United Kingdom
    N Engl J Med 357:28-38. 2007
    ..A recent meta-analysis raised concern regarding an increased risk of myocardial infarction and death from cardiovascular causes associated with rosiglitazone treatment of type 2 diabetes...
  73. ncbi request reprint Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure
    Mattie J Lenzen
    Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands
    Eur Heart J 26:2706-13. 2005
    ..Evidence-based medicine and clinical guidelines are based on the results of randomized controlled trials. Therefore, we investigated how patients who fulfilled the enrolment criteria of randomized trials were treated in real life...
  74. ncbi request reprint International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey
    Mitja Lainscak
    Department of Internal Medicine, General Hospital Murska Sobota, Murska Sobota, Slovenia
    Eur J Heart Fail 9:292-9. 2007
    ..This may reflect a lack of adequate organisation of care or co-morbidity contra-indicating therapy...
  75. ncbi request reprint Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
    Philip A Poole-Wilson
    National Heart and Lung Institute, Imperial College, London, UK
    Lancet 362:7-13. 2003
    ..We aimed to compare the effects of carvedilol and metoprolol on clinical outcome...
  76. ncbi request reprint Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology
    Markku S Nieminen
    Division of Cardiology, Helsinki University Central Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland
    Eur Heart J 26:384-416. 2005
  77. ncbi request reprint Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET
    Karl Swedberg
    Department of Medicine, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
    Eur Heart J 26:1303-8. 2005
    ..Atrial fibrillation is common in patients with chronic heart failure (CHF). We analysed the risk associated with atrial fibrillation in a large cohort of patients with chronic heart failure all treated with a beta-blocker...
  78. ncbi request reprint Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET
    Christian Torp-Pedersen
    Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark
    Am Heart J 149:370-6. 2005
    ..Beta-blockers with different receptor bindings reduce mortality in patients with chronic heart failure. We compared the effects of the beta1-blocker metoprolol tartrate and the beta1-, beta2-, and alpha1-blocker carvedilol...
  79. ncbi request reprint Familial hypertrophic cardiomyopathy: the same mutation, different prognosis. Comparison of two families with a long follow-up
    Dulce Brito
    Serviço de Cardiologia do Hospital de Santa Maria, Lisboa, Portugal
    Rev Port Cardiol 22:1445-61. 2003
    ..The complexity of hypertrophic cardiomyopathy makes it difficult to accurately determine genotype-phenotype relationships, and the screening and comparison of large affected families carrying the same mutation is warranted...
  80. ncbi request reprint The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN)
    Willem J Remme
    Sticares Cardiovascular Research Foundation, Rhoon, The Netherlands
    Cardiovasc Drugs Ther 18:57-66. 2004
    ..CARMEN explored the need for combined treatment for remodelling and order of introduction by comparing the ACE-I enalapril against carvedilol and their combination...
  81. ncbi request reprint The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design
    Peter Carson
    Department of Veterans Affairs Medical Center, Georgetown University Hospital, Washington, DC 20420, USA
    J Card Fail 11:576-85. 2005
    ..Although 40% to 50% of patients with chronic heart failure (HF) have relatively preserved systolic function (PSF), few trials have been conducted in this population and treatment guidelines do not include evidence-based recommendations...
  82. ncbi request reprint Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial)
    Andrea Di Lenarda
    Department of Cardiology, Ospedale di Cattinara, Strada di Fiume 447, 34100 Trieste, Italy
    Eur J Heart Fail 7:640-9. 2005
    ..metoprolol tartrate, a beta1-selective blocker, in patients with mild-to-severe chronic heart failure (CHF). Patients on treatment with metoprolol might benefit from switching to carvedilol...
  83. ncbi request reprint Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects
    Dougal R McClean
    Christchurch Hospital, Christchurch, New Zealand
    J Am Coll Cardiol 39:2034-41. 2002
    ..We investigated the acute and long-term hemodynamic and neurohumoral effects of the vasopeptidase inhibitor omapatrilat in human heart failure...
  84. ncbi request reprint A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET)
    John G F Cleland
    Department of Cardiology, University of Hull, Kingston upon Hull, United Kingdom
    J Am Coll Cardiol 47:1603-11. 2006
    ..This study was designed to investigate the loss of well-being, in terms of life-years, overall and in patients randomized to metoprolol versus carvedilol in the Carvedilol Or Metoprolol European Trial (COMET)...
  85. ncbi request reprint Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial
    Marco Metra
    Cattedra di Cardiologia, Universita di Brescia, Italy
    Eur Heart J 26:2259-68. 2005
    ....
  86. ncbi request reprint Mutations in the Z-band protein myopalladin gene and idiopathic dilated cardiomyopathy
    Laetitia Duboscq-Bidot
    INSERM, U621, Paris F 75013 France
    Cardiovasc Res 77:118-25. 2008
    ..Focusing on gene products located in the sarcomere of cardiomyocytes as disease-causing candidates, we screened the gene encoding the sarcomeric Z-band protein myopalladin (MYPN, OMIM 608517) for mutation...
  87. ncbi request reprint Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET
    Philip A Poole-Wilson
    Cardiac Medicine, National Heart and Lung Institute, Faculty of Medicine, Imperial College, Dovehouse Street, London, SW3 6LY, UK
    Eur J Heart Fail 4:321-9. 2002
    ..The target dose for carvedilol is 25 mg bid and for metoprolol tartrate 50 mg bid. This manuscript outlines the rationale, design and possible outcomes of COMET...
  88. ncbi request reprint Familial and sporadic hypertrophic myopathy: differences and similarities in a genotyped population. A long follow-up study
    Dulce Brito
    Clínica Universitária de Cardiologia, Faculdade de Medicina de Lisboa, Portugal
    Rev Port Cardiol 27:147-73. 2008
    ..A mutation is identified in two-thirds of cases, and more frequently in familial forms. Doubts remain concerning the true identity of the sporadic form...
  89. ncbi request reprint [European study of ambulatory management of heart failure by cardiologists]
    María J Salvador
    Rev Esp Cardiol 57:1170-8. 2004
    ..This cross-sectional study examined the overall clinical characteristics and management of 1252 outpatients with heart failure in 3 countries (Spain, France and Germany)...
  90. ncbi request reprint EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population
    Markku S Nieminen
    Division of Cardiology, Department of Medicine, Helsinki University Central Hospital, Haartmaninkatu 4, PO Box 340, 00029 HUS, Finland
    Eur Heart J 27:2725-36. 2006
    ....
  91. ncbi request reprint Rosuvastatin in older patients with systolic heart failure
    John Kjekshus
    Department of Cardiology, University of Oslo, Rikshospitalet University Hospital, Oslo, Norway
    N Engl J Med 357:2248-61. 2007
    ..Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients...
  92. ncbi request reprint Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET
    Marco Metra
    Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy
    Eur J Heart Fail 9:901-9. 2007
    ..We studied the relationship between changes in beta-blocker dose and outcome in patients surviving a HF hospitalisation in COMET...
  93. ncbi request reprint Comparative value of tissue Doppler imaging and m-mode color Doppler mitral flow propagation velocity for the evaluation of left ventricular filling pressure
    Michal Kidawa
    Department of Cardiology, Medical University of Łódź, Poland, Bieganski Hospital, ul Kniaziewicza 1 5, 91 347 Łódź, Poland
    Chest 128:2544-50. 2005
    ..However, little is known about the comparative value of these two indexes...
  94. ncbi request reprint [Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: executive summary (update 2005)]
    Karl Swedberg
    Sahlgrenska Academy, The Göteborg University, Goteborg, Sweden
    Rev Esp Cardiol 58:1062-92. 2005
  95. ncbi request reprint [Diagnosis and treatment of chronic heart disease. Guidelines of the European Society of Cardiology. Revision 2005]
    Karl Swedberg
    Sahlgrenska Academy at the Göteborg University, Department of Medicine, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
    Kardiol Pol 63:509-43; discussion 544-8. 2005
  96. ncbi request reprint Anemia in chronic heart failure: should we treat it and how?
    Michel Komajda
    J Am Coll Cardiol 49:763-4. 2007
  97. ncbi request reprint Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET
    Willem J Remme
    Sticares Cardiovascular Research Institute, Rhoon, The Netherlands
    J Am Coll Cardiol 49:963-71. 2007
    ..We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study...
  98. ncbi request reprint Nonpharmacologic measures and drug compliance in patients with heart failure: data from the EuroHeart Failure Survey
    Mitja Lainscak
    Department of Internal Medicine, General Hospital Murska Sobota, Murska Sobota, Slovenia
    Am J Cardiol 99:31D-37D. 2007
    ..In addition, a substantial proportion of those who recall the advice follow it incompletely. Younger age and prescription of appropriate pharmacologic treatment are associated with higher rates of recall and implementation...
  99. ncbi request reprint Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure
    Andrzej Gackowski
    Institute of Cardiology, Hospital Pitié Salpêtrière, Paris, France Department of Coronary Disease, Institute of Cardiology, Krakow, Poland
    Eur Heart J 25:1788-96. 2004
    ..Comparison of the value of echocardiography and B-type natriuretic peptide (BNP) in monitoring response to treatment in patients admitted for acute heart failure (HF)...
  100. ncbi request reprint A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET)
    John G F Cleland
    University of Hull, Kingston upon Hull, UK
    Cardiovasc Drugs Ther 18:139-52. 2004
    ..The purpose of this report is to describe in greater detail the heterogeneity of this population at baseline with particular reference to the impact of symptomatic severity, age and gender on patient characteristics...
  101. ncbi request reprint The safety of amiodarone in patients with heart failure
    Christian Torp-Pedersen
    Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark
    J Card Fail 13:340-5. 2007
    ..Uncertainty persists about the safety and efficacy of amiodarone for the management of heart failure...